Emily B. Harrison

Emily B. Harrison

Auto-generated profile, based on publicly available information

Emily B. Harrison

Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2016 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
EHEmily B. Harrison
Emily B. Harrison
CHColleen G. Hochfelder
Colleen G. Hochfelder
BLBenjamin G. Lamberty
Benjamin G. Lamberty
BMBrittney M. Meays
Brittney M. Meays
BMBrenda M. Morsey
Brenda M. Morsey
SYSowmya V. Yelamanchili
Sowmya V. Yelamanchili
Traumatic brain injury (TBI) is an important health concern and effective treatment strategies remain elusive. Understanding the complex multicellular response to TBI may provide new avenues for intervention. In the context of TBI, cell–cell communication is critical. One relatively unexplored form of cell–cell communication in TBI is extracellular vesicles (EVs). These membrane‐bound vesicles can carry many different types of cargo between cells. Recently, miRNA in EVs have been shown to mediate neuroinflammation and neuronal injury. To explore the role of EV‐associated miRNA in TBI, we isolated EVs from the brain of injured mice and controls, purified RNA from brain EVs, and performed miRNA sequencing. We found that the expression of miR‐212 decreased, while miR‐21, miR‐146, miR‐7a, and miR‐7b were significantly increased with injury, with miR‐21 showing the largest change between conditions. The expression of miR‐21 in the brain was primarily localized to neurons near the lesion site. Interestingly, adjacent to these miR‐21‐expressing neurons were activated microglia. The concurrent increase in miR‐21 in EVs with the elevation of miR‐21 in neurons, suggests that miR‐21 is secreted from neurons as potential EV cargo. Thus, this study reveals a new potential mechanism of cell–cell communication not previously described in TBI.

18 April 2019 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
MHMatthew J. Haney
Matthew J. Haney
NKNatalia L. Klyachko
Natalia L. Klyachko
EHEmily B. Harrison
Emily B. Harrison
YZYuling Zhao
Yuling Zhao
AKAlexander Kabanov
Alexander Kabanov
Elena BatrakovaElena Batrakova
Elena Batrakova

19 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMatthew J. Haney
Matthew J. Haney
YZYuling Zhao
Yuling Zhao
EHEmily B. Harrison
Emily B. Harrison
VMVivek Mahajan
Vivek Mahajan
SAShaheen Ahmed
Shaheen Ahmed
Elena BatrakovaElena Batrakova
Elena Batrakova
The ability to precisely upregulate genes in inflamed brain holds great therapeutic promise. Here we report a novel class of vectors, genetically modified macrophages that carry reporter and therapeutic genes to neural cells. Systemic administration of macrophages transfected ex vivo with a plasmid DNA ( p DNA) encoding a potent antioxidant enzyme, catalase, produced month-long expression levels of catalase in the brain resulting in three-fold reductions in inflammation and complete neuroprotection in mouse models of Parkinson's disease (PD). This resulted in significant improvements in motor functions in PD mice. Mechanistic studies revealed that transfected macrophages secreted extracellular vesicles, exosomes, packed with catalase genetic material, p DNA and mRNA, active catalase, and NF-κb, a transcription factor involved in the encoded gene expression. Exosomes efficiently transfer their contents to contiguous neurons resulting in de novo protein synthesis in target cells. Thus, genetically modified macrophages serve as a highly efficient system for reproduction, packaging, and targeted gene and drug delivery to treat inflammatory and neurodegenerative disorders.

18 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAlessandro Porrello
Alessandro Porrello
PLPatrick L. Leslie
Patrick L. Leslie
EHEmily B. Harrison
Emily B. Harrison
BGBalachandra K. Gorentla
Balachandra K. Gorentla
SKSravya Kattula
Sravya Kattula
CPChad V. Pecot
Chad V. Pecot
Lung cancer is the leading cause of cancer-related deaths worldwide, and lung squamous carcinomas (LUSC) represent about 30% of cases. Molecular aberrations in lung adenocarcinomas have allowed for effective targeted treatments, but corresponding therapeutic advances in LUSC have not materialized. However, immune checkpoint inhibitors in sub-populations of LUSC patients have led to exciting responses. Using computational analyses of The Cancer Genome Atlas, we identified a subset of LUSC tumors characterized by dense infiltration of inflammatory monocytes (IMs) and poor survival. With novel, immunocompetent metastasis models, we demonstrated that tumor cell derived CCL2-mediated recruitment of IMs is necessary and sufficient for LUSC metastasis. Pharmacologic inhibition of IM recruitment had substantial anti-metastatic effects. Notably, we show that IMs highly express Factor XIIIA, which promotes fibrin cross-linking to create a scaffold for LUSC cell invasion and metastases. Consistently, human LUSC samples containing extensive cross-linked fibrin in the microenvironment correlated with poor survival.

20 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHongxia Li
Hongxia Li
EHEmily B. Harrison
Emily B. Harrison
HLHuizhong Li
Huizhong Li
KHKoichi Hirabayashi
Koichi Hirabayashi
JCJing Chen
Jing Chen
HDHongwei Du
Hongwei Du
Metastatic non-small cell lung cancer (NSCLC) remains largely incurable and the prognosis is extremely poor once it spreads to the brain. In particular, in patients with brain metastases, the blood brain barrier (BBB) remains a significant obstacle for the biodistribution of antitumor drugs and immune cells. Here we report that chimeric antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR) exhibit antitumor activity in vitro against tumor cell lines and lung cancer organoids, and in vivo in xenotransplant models of orthotopic and metastatic NSCLC. The co-expression of the CCL2 receptor CCR2b in B7-H3.CAR-T cells, significantly improves their capability of passing the BBB, providing enhanced antitumor activity against brain tumor lesions. These findings indicate that leveraging T-cell chemotaxis through CCR2b co-expression represents a strategy to improve the efficacy of adoptive T-cell therapies in patients with solid tumors presenting with brain metastases.

13 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PLPatrick L. Leslie
Patrick L. Leslie
YCYvonne L. Chao
Yvonne L. Chao
YTYi-Hsuan Tsai
Yi-Hsuan Tsai
SGSubrata K. Ghosh
Subrata K. Ghosh
APAlessandro Porrello
Alessandro Porrello
CPChad V. Pecot
Chad V. Pecot
Lymph node (LN) metastases correspond with a worse prognosis in nearly all cancers, yet the occurrence of cancer spreading from LNs remains controversial. Additionally, the mechanisms explaining how cancers survive and exit LNs are largely unknown. Here, we show that breast cancer patients frequently have LN metastases that closely resemble distant metastases. In addition, using a microsurgical model, we show how LN metastasis development and dissemination is regulated by the expression of a chromatin modifier, histone deacetylase 11 (HDAC11). Genetic and pharmacologic blockade of HDAC11 decreases LN tumor growth, yet substantially increases migration and distant metastasis formation. Collectively, we reveal a mechanism explaining how HDAC11 plasticity promotes breast cancer growth as well as dissemination from LNs and suggest caution with the use of HDAC inhibitors.